Fosdin Pack

Fosdin Pack

calcium citrate + vitamin d3

alendronic acid




MedChoice Endocrine Group
Concise Prescribing Info
Per Weekly (round) FC tab Alendronic acid 70 mg. Per Daily (oval) tab Ca citrate 1.5 g, cholecalciferol (vit D3) 200 IU
Treatment of osteoporosis in postmenopausal women & increases bone mass in men w/ osteoporosis.
Dosage/Direction for Use
Adult Treatment of osteoporosis in postmenopausal women & to increase bone mass in men w/ osteoporosis 1 Wkly (round) tab once a wk & 1 Daily (oval) tab every day for 7 days (do not take w/ Wkly tab simultaneously).
Daily tab: Should be taken with food.. Weekly FC tab: Should be taken on an empty stomach: Take w/ a full glass of plain water at least 30 min before the 1st food/drink/medication of the day & remain in sitting/upright position for at least 30 min. Swallow whole, do not chew/dissolve in the mouth.
Hypersensitivity. Alendronic acid: GI diseases eg, duodenitis, dysphagia, symptomatic GERD, pyrosis, gastritis, gastroesophageal reflux, hiatal hernia & peptic ulcer. Patients w/ CrCl <35 mL/min (0.58 mL/sec). Hypocalcemia (primary or secondary) or vit D deficiency. Ca citrate & vit D3: Hypercalcemia (primary or secondary), hypercalciuria, kidney calculus; sarcoidosis; dehydration or electrolyte imbalance; chronic diarrhea or GI malabsorption; hypercalcemia; end stage renal failure; history of kidney stones; idiosyncrasy.
Special Precautions
Adverse Reactions
Abdominal pain. Rarely, unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis.
Drug Interactions
Alendronic acid: Absorption may be interfered if taken w/ food, nutritional supplements (Ca) or drugs (antacids). Doubled the bioavailability w/ IV ranitidine. Increased incidence of adverse events of the upper GIT w/ salicylate compd. Increased risk of hypoglycemia w/ aminoglycosides. Reduced absorption of Ca & Fe salts. Drugs which absorption may be modified w/ the presence of high doses of Ca. Decreased absorption w/ alcohol & caffeine intake & tobacco use. Reduced response w/ Ca-channel blockers. Reduced Ca absorption w/ high amounts of food intake w/ fiber, grains, cereals or phytates. Antagonized hypercalcemia treatment w/ calcitonin. May induce hypercalcemia w/ thiazide diuretics. Increased Ca absorption w/ estrogens. Decreases absorption of bisphosphonates. Reduced bioavailability w/ phenytoin. Reduced absorption w/ fluoroquinolones. Decreased absorption w/ Na fluoride. Diminishes the effect of cellulose Na phosphate. May increase the potential of Ca deposits in soft tissues w/ K phosphate/Na phosphate. Decreased absorption w/ Fe. Reduced Ca levels in the blood w/ gallium nitrate. Hypercalcemia or hypermagnesemia w/ Ca or Mg-containing prep. Milk-alkali syndrome w/ dairy products & Na bicarbonate. Reduced absorption w/ tetracyclines. Stimulates bone loss & counteracts the effects of Ca supplementation & may cause hypercalcemia w/ vit A (>7500 RE or >25,000 IU). Increases intestinal absorption of Ca w/ vit D, calciferol & calcitriol. Decreases from normal levels of serum phosphate.
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BB05 - alendronic acid, calcium and colecalciferol, sequential ; Belongs to the class bisphosphonates, combinations. Used in the treatment of bone diseases.
Fosdin pack
1 × 8's (P365/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in